Humacyte Cash Per Share vs. Return On Equity
| HUMA Stock | USD 5.29 0.78 17.29% |
Cash Per Share | First Reported 2010-12-31 | Previous Quarter 0.77787483 | Current Value 0.74 | Quarterly Volatility 1.57824642 |
For Humacyte profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Humacyte to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Humacyte utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Humacyte's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Humacyte over time as well as its relative position and ranking within its peers.
Humacyte |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Quarterly Revenue Growth (1.00) | Return On Assets (0.53) | Return On Equity (8.51) |
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Humacyte Return On Equity vs. Cash Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Humacyte's current stock value. Our valuation model uses many indicators to compare Humacyte value to that of its competitors to determine the firm's financial worth. Humacyte is rated # 5 in cash per share category among its peers. It is rated # 4 in return on equity category among its peers . At present, Humacyte's Cash Per Share is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Humacyte's earnings, one of the primary drivers of an investment's value.Humacyte Return On Equity vs. Cash Per Share
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Humacyte |
| = | 1.84 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Humacyte |
| = | -8.51 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Humacyte Return On Equity Comparison
Humacyte is currently under evaluation in return on equity category among its peers.
Humacyte Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Humacyte, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Humacyte will eventually generate negative long term returns. The profitability progress is the general direction of Humacyte's change in net profit over the period of time. It can combine multiple indicators of Humacyte, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -100 M | -105 M | |
| Income Before Tax | -110.8 M | -116.3 M | |
| Total Other Income Expense Net | -10.7 M | -10.2 M | |
| Net Loss | -13.8 M | -14.4 M | |
| Net Loss | -110.8 M | -116.3 M | |
| Net Interest Income | -774 K | -812.7 K | |
| Interest Income | 5.7 M | 6 M | |
| Net Loss | -89.4 M | -84.9 M | |
| Income Tax Expense | 3.1 M | 3.3 M | |
| Non Operating Income Net Other | 90.6 M | 75.8 M | |
| Change To Netincome | -63 M | -59.8 M | |
| Net Loss | (1.07) | (1.12) | |
| Income Quality | 0.66 | 0.63 | |
| Net Loss | (6.17) | (5.86) |
Humacyte Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Humacyte. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Humacyte position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Humacyte's important profitability drivers and their relationship over time.
Use Humacyte in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Humacyte position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Humacyte will appreciate offsetting losses from the drop in the long position's value.Humacyte Pair Trading
Humacyte Pair Trading Analysis
The ability to find closely correlated positions to Humacyte could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Humacyte when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Humacyte - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Humacyte to buy it.
The correlation of Humacyte is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Humacyte moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Humacyte moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Humacyte can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Humacyte position
In addition to having Humacyte in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Warren Buffett Holdings Thematic Idea Now
Warren Buffett Holdings
A long-term portfolio of publicly-traded stocks on US exchanges that are owned by Warren Buffett's holding company Berkshire Hathaway. The Warren Buffett Holdings theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Warren Buffett Holdings Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
To fully project Humacyte's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Humacyte at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Humacyte's income statement, its balance sheet, and the statement of cash flows.